Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic hematopoietic stem-cell transplantation

Transplantation

Volumn 88, Issue 4, 2009, Pages 528-532

  Danzer, Martin ^a   Polin, Helene ^a   Pröll, Johannes ^a   Haunschmid, Reinhard ^b   Hofer, Katja ^a   Stabentheiner, Stephanie ^a   Hackl, Christa ^a   Kasparu, Hedwig ^c   König, Josef ^c   Hauser, Hanns ^c   Binder, Michaela ^c   Weiss, Richard ^d   Gabriel, Christian ^a   Krieger, Otto ^c  

^a Red Cross Transfusion Service of Upper Austria   (Austria)

^b Federal Agency for Water Management   (Austria)

^c ELISABETHINEN HOSPITAL   (Austria)

^d UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; HLA E; Transplant related mortality

Indexed keywords

DNA; HLA E ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT RECIPIENT; GRAFT SURVIVAL; HOMOZYGOSITY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; SURVIVAL TIME;

ACUTE DISEASE; ADULT; AGED; BASE SEQUENCE; COHORT STUDIES; DNA PRIMERS; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROZYGOTE; HLA ANTIGENS; HOMOZYGOTE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 70349153871     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b0e79e     Document Type: Article

References (25)

1. Bogunia-Kubik K, Wysoczanska B, Lange A. Non-HLA gene polymorphisms and the outcome of allogeneic hemato-poietic stem cell transplantation. Curr Stem Cell Res Ther 2006; 1: 239.
2. Sullivan LC, Clements CS, Rossjohn J, et al. The major histocompati-bility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity. Tissue Antigens 2008; 72: 415.
3. O'Callaghan CA, Bell JI. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 1998; 163: 129.
4. Marsh SG. Nomenclature for factors of the HLA system, update November 2008: WHO Nomenclature Committee for Factors of the HLA System. Tissue Antigens 2009; 73: 383.
5. Strong RK, Holmes MA, Li P, et al. HLA-E allelic variants. Correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J Biol Chem 2003; 278: 5082.
6. Braud VM, Allan DS, O'Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998; 391: 795.
7. Petrie EJ, Clements CS, Lin J, et al. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J Exp Med 2008; 205: 725.
8. Kaiser BK, Pizarro JC, Kerns J, et al. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci USA 2008; 105: 6696.
9. Borrego F, Masilamani M, Marusina AI, et al. The CD94/NKG2 family of receptors: From molecules and cells to clinical relevance. Immunol Res 2006; 35: 263.
10. Michaelsson J, Teixeira de Matos C, Achour A, et al. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002; 196: 1403.
11. Ulbrecht M, Martinozzi S, Grzeschik M, et al. Cutting edge: The human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000; 164: 5019.
12. Heinzel AS, Grotzke JE, Lines RA, et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8-T cells. J Exp Med 2002; 196: 1473.
13. Tamouza R, Busson M, Rocha V, et al. Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation. Transplantation 2006; 82: 1436.
14. Tamouza R, Rocha V, Busson M, et al. Association of HLA-E polymor-phismwithseverebacterialinfectionandearlytransplant-relatedmortality in matched unrelated bone marrow transplantation. Transplantation 2005; 80: 140.
15. Petersen FB, Bearman SI. Preparative regimens and their toxicity. In: Forman SJ, Blume KG, eds. Bone marrow transplantation. Berlin/Heidelberg, Blackwell Scientific Publications 1994, p 82.
16. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382.
17. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756.
18. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825.
20. Sokal RR, Rohlf FJ. Biometry: The principles and practice of statistics in biologicalresearch[ed.3].NewYork,W.H.Freeman & Company1995,p887.
21. Antoun A, Jobson S, Cook M, et al. Ethnic variability in human leukocyte antigen-E haplotypes. Tissue Antigens 2009; 73: 39.
22. Ball LM, Egeler RM. Acute GvHD: Pathogenesis and classification. Bone Marrow Transplant 2008; 41: 58.
23. Coupel S, Moreau A, Hamidou M, et al. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007; 109: 2806.
24. Tamouza R, Busson M, Fortier C, et al. HLA-E*0101 allele in homozy-gous state favors severe bacterial infections in sickle cell anemia. Hum Immunol 2007; 68: 849.
25. Lu L, Cantor H. Generation and regulation of CD8(-) regulatory T cells. Cell Mol Immunol 2008; 5: 401.